Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 13/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008924 | 0.89 | CHRNA7 (0.39) | CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL6007672 | 0.89 | CHRNA7 (0.39) | CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL6008664 | 0.88 | CHRNA7 (0.39) | CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL6008998 | 0.88 | CHRNA7 (0.39) | CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL6008486 | 0.87 | CHRNA7 (0.38) | CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL6008809 | 0.87 | CHRNA7 (0.38) | CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL6008776 | 0.87 | CHRNA7 (0.38) | CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL6009319 | 0.87 | CHRNA7 (0.38) | CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL6007576 | 0.86 | CHRNA7 (0.38) | CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL6009323 | 0.86 | CHRNA7 (0.39) | CHRNA7CHRNB2CHRNA4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067515-B2 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PFIZER INC. (US) | 2006-06-27 | — | — | US | claimed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | claimed |
| US-7067515-B2 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | CHRNA7 594/4885CHRNB2 1185/4885CHRNA4 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.